Status:
WITHDRAWN
Neonatal Vaccination Against Hepatitis B in Africa - Sero-survey in Senegal
Lead Sponsor:
Institut Pasteur
Conditions:
Hepatitis B
Eligibility:
All Genders
9+ years
Phase:
NA
Brief Summary
Chronic infection with hepatitis B virus (HBV) is a leading cause of death in adults in sub-Saharan Africa (SSA). Prior to the introduction of the hepatitis B vaccine, main modes of transmission in SS...
Detailed Description
Chronic infection with hepatitis B virus (HBV) is a leading cause of death in adults in sub-Saharan Africa (SSA). Each year, about 61,000 people are estimated to die of hepatocellular carcinoma (HCC) ...
Eligibility Criteria
Inclusion
- All mothers of children between 9 and 12 months of age registered in the SSDS of Niakhar, Bambey and Fatick, who accept a blood sample from her and their child.
Exclusion
- A child without a mother identified for sampling
- Failure to sign informed consent to participate in the NeoVac 2 study
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03829735
Start Date
November 1 2020
End Date
August 30 2021
Last Update
March 23 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.